Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Vion Inks Manufacturing Deal for Anticancer Agent

  • Ben Venue Laboratories will manufacture Vion Pharmaceuticals’ Cloretazine, its lead anticancer agent, under a manufacturing agreement. 

    Cloretazine, an alkylating agent, is being evaluated in a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia (AML) and a Phase II trial in elderly patients with previously untreated de novo poor-risk AML.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »